Skip to main content

Immune Globulin Infusion (Human) 100 mg/mL Medicare Part D Coverage

Brand name: GAMMAGARD Liquid
Dosage form
INJECTION, SOLUTION
Route
INTRAVENOUS; SUBCUTANEOUS
36%
of Medicare Part D plans
cover Immune Globulin Infusion (Human)
2,010 of 5,530 plans
4.8
Avg. formulary tier

Formulary Tier Distribution

How Medicare Part D plans classify Immune Globulin Infusion (Human). Lower tiers = lower copays.

Tier 1 - Preferred Generic 5%
104 plans • avg $0.00/mo
Tier 2 - Generic 0%
2 plans • avg $0.00/mo
Tier 4 - Non-Preferred Drug 0%
7 plans • avg $0.00/mo
Tier 5 - Specialty 93%
1,877 plans • avg $0.00/mo
Tier 6 - Select Care 1%
20 plans • avg $0.00/mo

Find the cheapest plan for Immune Globulin Infusion (Human)

Enter your ZIP code to compare every plan in your area side-by-side.

Compare Plans for Immune Globulin Infusion (Human) →

Get Immune Globulin Infusion (Human) Delivered to Your Door

Compare prices and get discounts from trusted online pharmacies

DrugCovered may earn commissions from pharmacy purchases. Prices and availability vary. Always consult your doctor before starting or changing medications.

Immune Globulin Infusion (Human) Medicare Coverage by State

Coverage rates and average costs vary significantly by state. Click a state to see the specific plans available there.

Frequently Asked Questions about Immune Globulin Infusion (Human)

36% of Medicare Part D plans cover Immune Globulin Infusion (Human). It is most commonly placed on Tier 5. Coverage varies by plan and geographic area.

Costs vary by plan. Enter your ZIP code above to see exact prices for plans in your area.

Immune Globulin Infusion (Human) is placed on Tier 5 by most Medicare Part D plans. Lower tier numbers generally mean lower copays.

0% of plans require prior authorization for Immune Globulin Infusion (Human). Prior authorization means your doctor must confirm the drug is medically necessary before the plan will cover it.

Coverage statistics based on CMS formulary data for plan year 2026. Data updated regularly. Methodology →